Eiry Roberts Net Worth

The estimated Net Worth of Eiry Roberts is at least 15.5 百万$ dollars as of 13 February 2024. Ms. Roberts owns over 1,114 units of Neurocrine Biosciences stock worth over 2,880,783$ and over the last 7 years she sold NBIX stock worth over 7,743,970$. In addition, she makes 4,899,920$ as Chief Medical Officer at Neurocrine Biosciences.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ms. Roberts NBIX stock SEC Form 4 insiders trading

Eiry has made over 21 trades of the Neurocrine Biosciences stock since 2019, according to the Form 4 filled with the SEC. Most recently she sold 1,114 units of NBIX stock worth 148,117$ on 13 February 2024.

The largest trade she's ever made was exercising 77,679 units of Neurocrine Biosciences stock on 7 December 2023 worth over 6,100,132$. On average, Eiry trades about 5,707 units every 60 days since 2018. As of 13 February 2024 she still owns at least 23,716 units of Neurocrine Biosciences stock.

You can see the complete history of Ms. Roberts stock trades at the bottom of the page.

Eiry Roberts biography

Eiry Wyn Roberts M.D. serves as Chief Medical Officer of the Company. Dr. Roberts was appointed Chief Medical Officer in January 2018 and is responsible for all clinical development and medical affairs activities at Neurocrine Biosciences. Dr. Roberts has over 25 years of research and development experience in the pharmaceutical industry across all phases of drug development from research through commercialization in multiple therapeutic areas, including neuroscience, inflammation, oncology and metabolic diseases. She joined Neurocrine Biosciences from Eli Lilly and Company where she had worked since May 1991. During her tenure at Eli Lily and Company Dr. Roberts held various positions of increasing responsibility, including Vice President, Clinical Pharmacology/Managing Director of Chorus a position she held from October 2014 until December 2017 and Vice President of R&D, BioMedicines Business Unit. At Eli Lilly Dr. Roberts was the Chair of the Medical Review Committee, where she was responsible for review and approval of all the integrated clinical plans for molecules in the Lilly portfolio. Dr. Roberts was accountable for early clinical development programs across all therapeutic areas within Lilly, as well as registration for new chemical entities and biproducts in Phase III development. During her time at Lilly, Dr. Roberts established a new therapeutic area, which resulted in the development of five potential novel medicines from Phase I through to approval, with two of them successfully receiving regulatory approval. Dr. Roberts also has extensive leadership and business development experience, including the management of strategic alliances, business partnerships and venture capital collaborations. Dr. Roberts is a physician who trained in pharmacology and medicine in the UK, qualifying from the University of London in 1987. Her post-graduate clinical training was in clinical pharmacology and cardiology at St. Bartholomew’s Hospital and the Royal London Hospital.

What is the salary of Eiry Roberts?

As the Chief Medical Officer of Neurocrine Biosciences, the total compensation of Eiry Roberts at Neurocrine Biosciences is 4,899,920$. There are 3 executives at Neurocrine Biosciences getting paid more, with Kevin Gorman having the highest compensation of 9,450,830$.

How old is Eiry Roberts?

Eiry Roberts is 56, she's been the Chief Medical Officer of Neurocrine Biosciences since 2018. There are 11 older and 12 younger executives at Neurocrine Biosciences. The oldest executive at Neurocrine Biosciences, Inc. is William Rastetter, 72, who is the Independent Chairman of the Board.

What's Eiry Roberts's mailing address?

Eiry's mailing address filed with the SEC is 12780, El Camino Real, San Diego, San Diego County, California, 92014, United States.

Insiders trading at Neurocrine Biosciences

Over the last 22 years, insiders at Neurocrine Biosciences have traded over 159,913,426$ worth of Neurocrine Biosciences stock and bought 103,400 units worth 589,660$ . The most active insiders traders include Partners L P/Ilbiotechnolog...、Partners L P/Ilbiotechnolog...、Richard F Pops. On average, Neurocrine Biosciences executives and independent directors trade stock every 8 days with the average trade being worth of 1,567,813$. The most recent stock trade was executed by William H Rastetter on 15 August 2024, trading 14,250 units of NBIX stock currently worth 2,090,333$.

What does Neurocrine Biosciences do?

neurocrine biosciences, inc of san diego is a product based biopharmaceutical company focusing on the development and commercialization of innovative pharmaceutical products to treat unmet medical needs. the company's research and development efforts are focused on neurological and endocrine diseases and disorders. our product candidates address some of the largest pharmaceutical markets in the world including endometriosis, irritable bowel syndrome, anxiety, depression, pain, diabetes, insomnia, and other neurological and endocrine related diseases and disorders

Complete history of Ms. Roberts stock trades at Amicus Therapeutics Inc、Neurocrine Biosciences

Neurocrine Biosciences executives and stock owners

Neurocrine Biosciences executives and other stock owners filed with the SEC include:

• Kevin Gorman,
  Chief Executive Officer, Director
• Matthew Abernethy,
  Chief Financial Officer
• Eric Benevich,
  Chief Commercial Officer
• Eiry Roberts,
  Chief Medical Officer
• Haig Bozigian,
  Chief Development Officer
• Kyle Gano,
  Chief Business Development and Strategy Officer
• Dimitri Grigoriadis,
  Chief Research Officer
• Dr. Kevin C. Gorman Ph.D.,
  CEO & Director
• Dr. Eiry Wyn Roberts,
  Chief Medical Officer
• Leslie Norwalk,
  Independent Director
• Matthew C. Abernethy,
  Chief Financial Officer
• Eric S. Benevich,
  Chief Commercial Officer
• Kyle W. Gano,
  Chief Bus. Devel. and Strategy Officer
• William Rastetter,
  Independent Chairman of the Board
• Stephen Sherwin,
  Independent Director
• Richard Pops,
  Independent Director
• George Morrow,
  Independent Director
• Gary Lyons,
  Independent Director
• Todd Tushla,
  Investor Relations
• Julie Cooke,
  Chief Human Resource Officer
• Shalini Sharp,
  Independent Director
• Darin Lippoldt,
  Chief Legal Officer and Corporate Secretary
• Malcolm Lloyd-Smith,
  Chief Regulatory Officer
• David Boyer,
  Chief Corporate Affairs Officer
• Julie S. Cooke,
  Chief HR Officer
• Darin M. Lippoldt,
  Chief Legal Officer & Corp. Sec.
• Jane Sorensen,
  Head of Investor Relations
• Dr. Jude Onyia Ph.D.,
  Chief Scientific Officer
• Dr. Dimitri E. Grigoriadis,
  Chief Research Officer
• Matt Abernethy,
  Chief Financial Officer
• Corinne H Nevinny,
  Director
• Christopher Flint O Brien,
  Sr. VP & Chief Medical Officer
• Joseph A Mollica,
  Director
• David Alexandre C Gros,
  President & COO
• Alfred Sandrock,
  Director
• Christine A Poon,
  Director
• Wylie W Vale,
  Director
• Timothy Coughlin,
  VP and Chief Financial Officer
• Jensen Margaret E Valeur,
  Senior VP and General Counsel
• Partners L P/Ilbiotechnolog...,
  
• Johanna Mercier,
  Director
• Partners L P/Ilbiotechnolog...,
  
• Partners L P/Ilbiotechnolog...,
  
• Henry Pan,
  Executive VP and CMO
• Wendall Wierenga,
  EVP, Research & Development
• Richard J Ranieri,
  Sr. VP, Human Resources
• Thomas Mitchell W,
  Director
• Ingrid Delaet,
  Chief Regulatory Officer
• Paul W Hawran,
  Executive VP and CFO
• Paul J Conlon,
  Vice President Research (Biol)
• Lawrence Steinman,
  Director
• John Saunders,
  Vice President Research (Chem)
• Robert J Little,
  SVP, Commercial Operations
• D Bruce Campbell,
  Senior Vice President
• Jude Onyia,
  Chief Scientific Officer